XTalks

FEBRUARY 21, 2024

Tirzepatide’s mechanism of action involves activating two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Clinical Trials for MASH Treatment The tirzepatide trial involved approximately 190 adults with MASH at different stages.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

Delveinsight

AUGUST 2, 2020

Cachexia is observed as a result of underlying diseases, including cancer, AIDS, tuberculosis, chronic heart failure, hormonal deficiency, and others. The company is currently preparing for further clinical trials in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC). Cancer Cachexia Pipeline.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

DECEMBER 23, 2020

The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout. NT-814 is a non-hormonal drug that works on the neurokinin (NK) 1,3 receptor antagonist, thus treating the vasomotor symptoms associated with the menopause. Rare disease progress.

Marketing 78

Marketing Gene Silencing Gene Drugs 78

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. Pharma companies like Alnylam Pharmaceuticals , Ionis Pharmaceuticals , Eidos Therapeutics, and many others are providing the thrust to the Hereditary transthyretin amyloidosis market forward.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Roots Analysis

MAY 21, 2024

Due to which, several big pharma companies and other industry stakeholders are actively contributing towards development of protein degradation therapies and technologies, contributing towards growth of targeted protein degradation market. Currently, North America captures the largest share of targeted protein degradation market.

Protein 40

Protein Marketing Development Antibody 40

Delveinsight

DECEMBER 2, 2020

Hormones – It is observed that hormones differentially influence the onset of Rheumatoid Arthritis in premenopausal and postmenopausal women. However, the role of hormones is still unclear. Various researches are going on to find the exact link between the hormone and Rheumatoid Arthritis.

Marketing 60

Marketing Hormones Antibody Development 60